Loading...
VERV logo

Verve Therapeutics, Inc.NasdaqGS:VERV Stock Report

Market Cap US$991.5m
Share Price
US$11.13
US$15.11
26.3% undervalued intrinsic discount
1Y48.8%
7D1.6%
Portfolio Value
​
View

Verve Therapeutics, Inc.

NasdaqGS:VERV Stock Report

Market Cap: US$991.5m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Verve Therapeutics (VERV) Stock Overview

A clinical-stage company, develops gene editing medicines for patients to treat cardiovascular disease in the United States. More details

VERV fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Risk Analysis

Earnings are forecast to decline by an average of 15.7% per year for the next 3 years

Highly volatile share price over the past 3 months compared to the US market

Currently unprofitable and not forecast to become profitable over the next 3 years


VERV Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Verve Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Verve Therapeutics
Historical stock prices
Current Share PriceUS$11.13
52 Week HighUS$11.41
52 Week LowUS$2.86
Beta2.24
1 Month Change-0.36%
3 Month Change93.23%
1 Year Change48.80%
3 Year Change-59.60%
5 Year Changen/a
Change since IPO-65.13%

Recent News & Updates

Seeking Alpha • Jun 17

Verve Therapeutics' Lifeline: Eli Lilly's $1.3 Billion Bet On Cardiovascular Gene Therapy (Upgrade)

Summary Eli Lilly's $1.3B offer for Verve Therapeutics is a lifeline, providing a 70%+ premium and a solid exit for Verve investors. VERV struggled as a standalone due to tough gene therapy commercialization and competition from established cardiovascular treatments like statins and PCSK9 inhibitors. For LLY, the acquisition diversifies its pipeline and positions it for future innovation in chronic disease, despite high risk and uncertain payoff. The deal is mutually beneficial: Verve gets a strong exit, while Eli Lilly makes a speculative, forward-looking bet with its abundant cash reserves. Read the full article on Seeking Alpha

Recent updates

Seeking Alpha • Jun 17

Verve Therapeutics' Lifeline: Eli Lilly's $1.3 Billion Bet On Cardiovascular Gene Therapy (Upgrade)

Summary Eli Lilly's $1.3B offer for Verve Therapeutics is a lifeline, providing a 70%+ premium and a solid exit for Verve investors. VERV struggled as a standalone due to tough gene therapy commercialization and competition from established cardiovascular treatments like statins and PCSK9 inhibitors. For LLY, the acquisition diversifies its pipeline and positions it for future innovation in chronic disease, despite high risk and uncertain payoff. The deal is mutually beneficial: Verve gets a strong exit, while Eli Lilly makes a speculative, forward-looking bet with its abundant cash reserves. Read the full article on Seeking Alpha
Analysis Article • May 28

Verve Therapeutics, Inc. (NASDAQ:VERV) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely

Unfortunately for some shareholders, the Verve Therapeutics, Inc. ( NASDAQ:VERV ) share price has dived 26% in the last...
Analysis Article • May 19

News Flash: Analysts Just Made An Incredible Upgrade To Their Verve Therapeutics, Inc. (NASDAQ:VERV) Forecasts

Verve Therapeutics, Inc. ( NASDAQ:VERV ) shareholders will have a reason to smile today, with the analysts making...
Seeking Alpha • Apr 16

Verve Therapeutics: FDA Fast Track And Eli Lilly Partnership Upgrade It To A 'Buy'

Summary VERV’s VERVE-102 showed an impressive 69% LDL-C reduction in its early Phase 1b data. Also, LLY may opt into VERVE-102’s development later this year, which would help VERV by covering one-third of the R&D costs. Similarly, VERV’s pipeline includes VERVE-201 for HoFH and refractory hypercholesterolemia, as well as VERVE-301 in collaboration with Lilly. And from a valuation perspective, the shares are cheaper than the first time I covered it. All while making great progress with its pipeline. So, ultimately, I think VERV remains a high-risk, long-term play in gene editing. But its risk-reward profile now seems to justify a “Buy” rating. Read the full article on Seeking Alpha
Seeking Alpha • Mar 25

Verve Therapeutics: HeFH Treatment Program Of VERVE-102 Remains On Track With 2025 Catalysts

Summary Company received FDA IND clearance for VERVE-102 to treat HeFH, adding new trial sites in the United States. The switch to the Gal-NAc LNP delivery system aims to improve safety, avoiding clinical abnormalities observed with VERVE-101. Key upcoming catalysts include initial phase 1b Heart-2 data in Q2 2025, final dose-escalation data, and potential Eli Lilly opt-in for PCSK9 inhibitor program in the 2nd half of 2025. Atherosclerotic Cardiovascular Disease, in the 7 Major Markets, is expected to reach $30.6 billion by 2035. Read the full article on Seeking Alpha
Seeking Alpha • Feb 28

Verve Therapeutics: Key Data Catalysts, Major Share Price Volatility In Play In Q2

Summary Verve Therapeutics' stock remains a "Buy" despite recent setbacks, including the retirement of its Chief Medical Officer and the termination of a collaboration with Vertex. Verve's gene-editing programs aim to transform cardiovascular disease treatment by permanently lowering cholesterol through a one-time intravenous infusion, offering significant therapeutic and commercial potential. The upcoming data readout for Verve-102 in 2025 is crucial; success could attract Eli Lilly's partnership, while failure may question the entire base editing approach. Despite leadership changes and challenges, Verve's innovative approach and potential for groundbreaking treatments justify a high-risk, high-reward investment strategy. Read the full article on Seeking Alpha
Analysis Article • Dec 08

Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Aug 30

Verve Therapeutics: An In Vivo Gene Editing 'Moon Shot' For Your Portfolio

Summary Verve Therapeutics aims to revolutionize cardiovascular disease treatment with single-course gene editing, despite facing significant challenges and setbacks in clinical trials. The company's lead assets, VERVE-101 and VERVE-102, target the PCSK9 gene to lower LDL-C levels, but safety issues have hindered progress. Verve-102, using a different delivery technology, is now the focus, with initial data expected in 1H25, presenting a crucial milestone for investors. Partnerships with Eli Lilly, Beam Therapeutics, and Vertex offer potential financial support and validation, but Verve remains a high-risk, high-reward investment. Read the full article on Seeking Alpha
Analysis Article • Aug 10

Earnings Release: Here's Why Analysts Cut Their Verve Therapeutics, Inc. (NASDAQ:VERV) Price Target To US$25.78

As you might know, Verve Therapeutics, Inc. ( NASDAQ:VERV ) just kicked off its latest second-quarter results with some...
Analysis Article • Jul 12

We're Not Very Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Jun 13

Why Verve Therapeutics Deserves A Spot On Your Watchlist

Summary Verve Therapeutics focuses on gene editing technology for one-dose therapies to reduce lipid levels related to ASCVD. VERV's pipeline includes therapies targeting genes like PCSK9, ANGPTL3, and LPA to lower ASCVD risk. Verve's leading programs, VERVE-101 and VERVE-102, target heterozygous familial hypercholesterolemia (HeFH), with VERVE-101 in clinical trials and VERVE-102 in the IND-enabling stage. Financially, Verve has a strong cash position, with $606.3 million in liquidity and a cash runway of approximately 3.5 years. VERV's research is in the early stages, making it a speculative investment, but it is worth adding to a watchlist as research progresses. Read the full article on Seeking Alpha
Analysis Article • May 14

Broker Revenue Forecasts For Verve Therapeutics, Inc. (NASDAQ:VERV) Are Surging Higher

Verve Therapeutics, Inc. ( NASDAQ:VERV ) shareholders will have a reason to smile today, with the analysts making...
Analysis Article • May 12

The Verve Therapeutics, Inc. (NASDAQ:VERV) First-Quarter Results Are Out And Analysts Have Published New Forecasts

As you might know, Verve Therapeutics, Inc. ( NASDAQ:VERV ) just kicked off its latest first-quarter results with some...
Seeking Alpha • Apr 03

Verve Therapeutics Stock Remains A Hold After VERVE-101 Enrollment Pause

Summary Enrollment paused in the Verve Therapeutics' phase 1b heart-1 study, using VERVE-101 for the treatment of patients with heterozygous familial hypercholesterolemia after a Grade 3 adverse event. Despite VERVE-101 setback, the ability to move forward with another PCSK9 inhibitor known as VERVE-102 where the phase 1b heart-2 study is expected to begin any day now in Q2 2024. VERVE-102 could be a major change in structure because it has two distinct features compared to its predecessor, which are a different ionizable lipid and the GalNAc delivery system. Partnership with Eli Lilly remains in place for now, despite VERVE-101 enrollment being paused. Read the full article on Seeking Alpha
Analysis Article • Feb 28

Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Feb 13

Verve's Proof-Of-Concept Data Doesn't Inspire Confidence

Summary Verve Therapeutics aims to revolutionize cardiovascular disease treatment with gene therapy. Recent VERVE-101 data shows LDL-C reduction comparable to existing drugs but with serious adverse events in two patients, raising safety concerns. Verve's financials show a solid runway with ~$600 million in liquid assets after a recent capital infusion, but ongoing and future trials will demand substantial funding. Recommendation: Sell. Despite proof-of-concept and a one-time treatment appeal, safety concerns and competitive landscape challenge its long-term valuation. Read the full article on Seeking Alpha
Seeking Alpha • Jan 14

Vectoring In On Verve Therapeutics

Summary Verve Therapeutics aims to revolutionize treatment for cardiovascular disease through in vivo gene therapy using base editing technology. Their lead candidate, VERVE-101, has shown promising results in reducing LDL-C levels in preclinical studies. Verve has partnerships with Beam Therapeutics, Eli Lilly, and Vertex Pharmaceuticals, and analysts have a positive outlook on the company. A full investment analysis around Verve Therapeutics stock is presented in the paragraphs below. Read the full article on Seeking Alpha
Analysis Article • Jun 07

Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article • Feb 24

Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Nov 09

We Think Verve Therapeutics (NASDAQ:VERV) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Sep 20

Verve Therapeutics: Cathie Wood Adds To ARKK

Summary ARKG component added to flagship fund. Meaningful position would top 7% of outstanding shares. Company fits usual pattern with large losses and cash burn.

Shareholder Returns

VERVUS BiotechsUS Market
7D1.6%-3.0%-0.3%
1Y48.8%32.9%26.7%

Return vs Industry: VERV exceeded the US Biotechs industry which returned -9.5% over the past year.

Return vs Market: VERV exceeded the US Market which returned 17.7% over the past year.

Price Volatility

Is VERV's price volatile compared to industry and market?
VERV volatility
VERV Average Weekly Movement24.9%
Biotechs Industry Average Movement10.9%
Market Average Movement7.2%
10% most volatile stocks in US Market16.2%
10% least volatile stocks in US Market3.2%

Stable Share Price: VERV's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: VERV's weekly volatility has increased from 18% to 25% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2018274Sek Kathiresanwww.vervetx.com

Verve Therapeutics, Inc., a clinical-stage company, develops gene editing medicines for patients to treat cardiovascular disease in the United States. The company’s product candidates include VERVE-101, which is being evaluated in the Heart-1 trial, an open-label Phase 1b clinical trial, as well as changes in blood PCSK9 protein and LDL-C levels in patients living with heterozygous familial hypercholesterolemia (HeFH); VERVE-102 that is being evaluated in the Heart-2 trial, an open-label Phase 1b clinical trial in adult patients with HeFH, and/or premature coronary artery diseases; VERVE-201, which targets ANGPTL3 and permanently turn off the ANGPTL3 gene in the liver; and VERVE-301, a development candidate that uses a novel in vivo gene editing approach to permanently turn off the LPA gene in the liver to reduce blood Lp(a) levels. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; a license agreement to lipid technology with Novartis Pharma AG; Eli Lilly and Company; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College.

Verve Therapeutics, Inc. Fundamentals Summary

How do Verve Therapeutics's earnings and revenue compare to its market cap?
VERV fundamental statistics
Market capUS$991.46m
Earnings (TTM)-US$181.01m
Revenue (TTM)US$59.61m
16.7x
P/S Ratio
-5.5x
P/E Ratio

Is VERV overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VERV income statement (TTM)
RevenueUS$59.61m
Cost of RevenueUS$210.43m
Gross Profit-US$150.82m
Other ExpensesUS$30.19m
Earnings-US$181.01m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-2.03
Gross Margin-252.99%
Net Profit Margin-303.64%
Debt/Equity Ratio0%

How did VERV perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/24 17:34
End of Day Share Price 2025/07/24 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Verve Therapeutics, Inc. is covered by 4 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Andrea NewkirkGoldman Sachs
Andrea NewkirkGoldman Sachs
Mitchell KapoorH.C. Wainwright & Co.